07/04/2026
Babraham Research Campus has announced a new partnership with Bio-Rad Laboratories, a global leader in life science research and clinical diagnostics products, to provide LiveLabs members with access to advanced chromatography capabilities.
Through the partnership, Bio-Rad will provide an NGC™ Chromatography System for shared use within the Meditrina laboratory space, supporting protein purification and workflow optimisation for early-stage biotechnology companies and academic innovators based on campus.
The sponsorship includes:
The system will be housed within LiveLabs and supported directly by Bio-Rad’s service and applications teams, ensuring reliable access and continuity for resident scientists.
Access to advanced chromatography technologies is critical for protein purification, method development, and early-stage research programmes. By embedding shared infrastructure within LiveLabs, the partnership aims to:
This collaboration reinforces Babraham Research Campus’ position as a leading UK bioscience cluster, supporting innovation at the intersection of discovery and commercialisation.
Ruth Campbell, LiveLabs Manager said,
“This partnership will make a real difference for our LiveLabs members through access to new equipment and specialist Bio-Rad technical support, complementing the support already here on Campus. We’re looking forward to working closely with the Bio‑Rad team to deliver meaningful engagement and opportunities for our growing LiveLabs community.”
Reg Chopra, Director of EMEA marketing, Life Sciences at Bio-Rad, said,
“Babraham Research Campus plays a vital role in the UK life sciences ecosystem, bringing together entrepreneurial biotech companies and world-class research. By providing shared access to our NGC Chromatography System, along with technical training and ongoing support, Bio-Rad is reinforcing its commitment to enabling early-stage innovators with the infrastructure required to translate ideas into impact. This partnership builds on Bio-Rad’s broader engagement with UK innovation hubs and reflects its continued investment in collaborative research environments that support entrepreneurship, infrastructure access, and scientific advancement.”
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 7,700 employees, and $2.6 billion in revenues in 2024. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com.
About Babraham Research Campus
Babraham Research Campus is distinct in its co‐location of 60 bioscience companies with the Babraham Institute, a world‐renowned research organisation which receives strategic funding from the Biotechnology and Biological Sciences Research Council (BBSRC). The aim of the Campus is to support UK bioscience through academic research, but also with facilities and capabilities for early-stage and growing commercial organisations. The Campus provides companies laboratory and office space, networking and collaboration opportunities, together with access to outstanding scientific facilities in an ideal geographical location at the core of the Cambridge cluster.
Bio-Rad Forward-Looking Statements
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our collaboration with Pioneer Group, our products and our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include risks relating to our international operations, global economic and geopolitical conditions, tariffs or other trade barriers, reductions in government funding or capital spending of our customers, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, supply chain risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad's public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.